Voorbeelden van het gebruik van Supplementary indications in het Engels en hun vertalingen in het Nederlands
{-}
-
Colloquial
-
Official
-
Ecclesiastic
-
Medicine
-
Financial
-
Computer
-
Ecclesiastic
-
Official/political
-
Programming
Supplementary indications.
Extension of the deadline concerning the use of supplementary indications.
The use of supplementary indications shall be authorised.
For industry the status quo is preserved regarding supplementary indications.
The use of supplementary indications shall be authorized until 31 December 1989.
To extend the time limit for the use of supplementary indications until 31 December 2009.
The use of supplementary indications may be extended after 31 December 1989.
Option 1- No action: a sundown clause would mean that by end of 2009 supplementary indications are no longer allowed.
Extending the use of supplementary indications indefinitely the basic Directive provided for their use until the end of 2009.
Whereas Article 3(5) of Directive 80/181/EEC allows new final dates to be set for the use of supplementary indications.
The importance of using supplementary indications lies, for example, in trade with economic partners not using
To update the technical aspects of the directive and to allow products to continue to be placed on the European market with supplementary indications.
of Directive 80/181/EEC by extending the time allowed for the use of supplementary indications until 31 December 2009- ten years from the current deadline;
decisions, and extending the deadline concerning the use of supplementary indications.
The importance of the use of supplementary indications lies, for instance, in trade with economic partners which do
In the meantime, the EU should as an interim measure extend until 31 December 2009 the transition period during which supplementary indications in non-legal units are allowed.
Concerning the ending of the use of supplementary indications, written representations have been made and meetings have been held with industry groups over the period February to September 1998.
also allows the use of supplementary indications(without defining what they are)
The item of supplementary indications was also highlighted in the Trans-Atlantic Business Dialogue under the issue of‘metric labelling' in the 1997(Rome) and 1998(Charlotte, USA) meetings.
Without prejudice to Directive 80/181/EEC, Member States shall, after 31 December 1999, authorise or continue to permit the use of the supplementary indications referred to in Article 3 of that Directive.
Allowing the continued use of supplementary indications does not mean that the Community accepts the current non-tariff barriers in third countries against goods labelled exclusively in SI units.
continue to permit the use of the supplementary indications referred to in Article 3 of that Directive.
the indication of the nominal weight of prepackages to which this Article applies may be accompanied by a supplementary indication.
companies exporting their products to these countries will be disadvantaged if supplementary indications are disallowed after 31 December 1999; supplementary indications in non-legal units should therefore be authorised for a further period.
Supplementary indications are indications in those units not contained in Chapter I, i.e. units other
Until a level playing field is achieved where market forces can dictate the need for supplementary indications the European Union support for the use of the SI must be evidenced by setting the date for SI only indications. .
the matter of supplementary indications shall be further examined,
whereas companies exporting to these countries will be disadvantaged if supplementary indications are disallowed after 31 December 1999; whereas supplementary indications in non-legal units should therefore be authorised for a further period;
especially concerning supplementary indications, and to take the necessary measures in pursuit of a permanent solution to the incompatibilities with other legislation which affect the global market.
certain sectors of European industry allege that discontinuation of the allowance for supplementary indications would lead to high compliance costs without added value,